
RT @DrChoueiri: JUST IN: @FDA approves peri-operative PD-L1 inhibitor Durvalumab + EV in cis-ineligible/refusing Muscle-Invasive Bladder Ca…
✓
RT @DrChoueiri: JUST IN: @FDA approves peri-operative PD-L1 inhibitor Durvalumab + EV in cis-ineligible/refusing Muscle-Invasive Bladder Ca…

Clonal evolution. Wheler was here too but she left before the photo. Proud of these mentees and wonderful opportunity to see them at TargetCancer Foundation meeting for rare cancers. 🧨🦄🦓🎯💡👏

⭐️🚨Nivolumab/Ipilimumab and Pembrolizumab for All Cancers: Australia's Landmark Tumor-Agnostic Immunotherapy Reimbursement | Journal of Clinical Oncology @JCO_ASCO @ASCO @Dr_R_Kurzrock @OncoAlert ascopubs.org/doi/10.1200/JCO…

Proud to see @NazliDizman @DanaFarber on the main stage at @SWOG in our GU planning session. Grateful to @PBarataMD @caseccc (PI of S2419, BIOFRONT) & @BraunMDPhD @YaleCancer (GU translational lead) for getting her involved in analyzing biomarker results in the 1st P3 study evaluating microbiome modulation to improve IO-outcomes!

Such an honor to co-chair the WIN symposium with Wafik El Deiry

Living the WIN conference. Molecular Tumor Boards everywhere. Who knew that when we coined the term and concept in 2014, it would take off Iike wild fire!!

Congratulations to my good friend and colleague Mary-Ellen Taplin on the well deserved @PCFnews Women in Science Lifetime Achievement Award ! Thank you @PCF_Science for this important recognition! @DanaFarber_GU @DanaFarber @DanaFarberNews @harvardmed

🚨⭐️What an energizing LIVE molecular tumor board at the WIN Symposium , Providence, RI @WIN_Consortium world‑class precision oncology faculty tackling real & challenging cases in real time @Dr_R_Kurzrock @weldeiry @bickythapa02 @SewantiLimaye ⭐️Imagine if every patient everywhere had access to this level of expert discussion & insight @OncoAlert @oncodaily

The FDA voted in favor of the Galleri blood test for multicancer detection. @DanaFarber's @DrChoueiri tells @GoHealio this is an important milestone, but more long-term data are needed. Read more: bit.ly/4xPVaZh

JUST IN: @FDA approves the combo of Lenvatinib+HIF2 inhibitor Belzutifan in advanced clear cell renal cell carcinoma following PD1/L1 inhibitor. Results based on Litespark-011 trial led by @motzermd @DrDanielHeng @SchmidigerManu1 @ASCO @myESMO @AACR @kidneycan @DanaFarber_GU @OncoAlert

Dr @RashadNawfal is an outstanding prospect for internal medicine residency. He is a superb physician and under his belt he has multi-year laboratory experience in liquid biopsies and epigenomics from my lab and the Freedman lab @DanaFarber @DanaFarber_GU

I’m excited to join fellow experts and Shirley @leung at @BostonGlobe Media’s Future of Medicine Summit to discuss how cancer vaccines are rewriting the rules of treatment – exploring how personalized mRNA vaccines are moving from moonshot ideas to real clinical trials with real patients and real benefits! Join us on September 15 for a day of thought-provoking conversations about what’s next in healthcare. Learn more and register at Globe.com/futureofmedicine. #FutureofMed2026 @DanaFarber @DanaFarber_GU @DanaFarberNews @OnlyInBOS @ScienceinBoston @harvardmed @TheVinodLab #MichelleBrown

So thrilled to have you @neerajaiims with us at @DanaFarber! We are incredibly fortunate to welcome not only an outstanding prostate cancer oncologist, but also a terrific colleague and leader. Excited to see all that you will bring to our team and to the @Harvard Cancer Consortium #ProstateCancer Program. Welcome to @CityOfBoston and to the family! @DanaFarber_GU @harvardmed @DanaFarberNews @df_hcc

Very excited to welcome four outstanding new faculty to the Lank Center for Genitourinary Oncology @DanaFarber 1) Dr. Nazli Dizman @NazliDizman 2) Dr. Brian Russell @brian_russell39 3) Dr. Hamid Emamekhoo @HamidEmamekhoo 4) Pr. Neeraj Agarwal @neerajaiims They bring complementary expertise spanning clinical investigation, microbiome science, informatics, quality improvement, education, and GU oncology. Hamid and Neeraj will also take on important broader institutional leadership roles @DanaFarber and @Harvard Cancer Consortium @df_hcc We are fortunate to have them—and the @DanaFarber_GU and our patients are in very good hands. Welcome to @CityOfBoston and @DanaFarber!

The 5-year follow-up from KY-564 now published in @Annals_Oncology --the first ever adjuvant trial in Kidney cancer continues to show a survival benefit now with OS at 5+years and in key subgroups! annalsofoncology.org/article… @HaasNaomi @tompowles1 @OncoAlert @OncBrothers @DanaFarber_GU @DanaFarber @harvardmed @AUC3_Official

Have you ever wondered what takes place in a TCF-001 TRACK Virtual #MolecularTumorBoard meeting? Watch to learn how biomarker testing and multi-disciplinary expertise come together to uncover treatment options for difficult-to-treat #RareCancers targetcancer.short.gy/RCTT-2…